ImmuPharma PLC

www.immupharma.com News

Follow

Follow

Only registred members can create thier own customized alerts.

Help
Watchlist/Portfolio

Add to watchlist:
Only registered members can add into watchlist !

Register here !

ImmuPharma PLC RNS Press Releases

Page 1 of 8

17/04/12
Posting of Annual Report and AGM Notice
27/03/12
Preliminary Results
20/03/12
Notification of Full Year Results
29/02/12
Appoints Head of Investor Relations
24/01/12
Directors Dealings

27/03/12

Press: 27.03.12: -1.50, (70.00) Press: Immupharma fell after announcing increased annual losses of GBP3.35m, up from GBP1.98m. The company has... read more

Press: 27.03.12: -1.50, (70.00) Press: Immupharma fell after announcing increased annual losses of GBP3.35m, up from GBP1.98m. The company has regained the rights to its Lupuzor compound which it hopes will prove successful in treating Lupus, the potentially life-threatening autoimmune disease. Source - Mail
12/03/12

12.03.12 :-1, (74) Peel Hunt initiates coverage with a "sell" rating.

12.03.12 :-1, (74) Peel Hunt initiates coverage with a "sell" rating.
21/11/11
+0.50 +92.00

Merchant Securities initiates buy on ImmuPharma, target price 323p.

Merchant Securities initiates buy on ImmuPharma, target price 323p.
03/11/11
+17.00 +92.00

Press: Immupharma rose on news its Lupus drug treatment, Lupuzor, has been given approval to start phase III and fast track designation by the... read more

Press: Immupharma rose on news its Lupus drug treatment, Lupuzor, has been given approval to start phase III and fast track designation by the US Food & Drug Administration. Broker Panmure Gordon has a target price of 150p and says this approval makes the asset more attractive to partners. A cash rich pharma giant could now knock on the door and help the company finance expensive Phase III procedures. Source - Mail
21/10/11

Press: 21.10.11: -4.12, (74.38) Press: ImmuPharma fell on news that US drugmaker Cephalon had handed back development rights to its lupus... read more

Press: 21.10.11: -4.12, (74.38) Press: ImmuPharma fell on news that US drugmaker Cephalon had handed back development rights to its lupus treatment Lupuzor. Panmure Gordon analysts saw it as a positive that ImmuPharma would get a second chance to auction the drug. ?Assuming a willing partner is found, the company will be able to develop the product faster instead of having to coerce an unwilling partner,? it argued. Source - Financial Times

ImmuPharma PLC Articles

Page 1 of 5

20/04/12

ImmuPharma in broker spotlight after bid emerges for rival lupus drug maker

GlaxoSmithKline’s $2.6 billion hostile bid for Human Genome Science yesterday highlighted the commercial potential for biotech ImmuPharma's rival lupus drug, Lupuzor, suggest analysts.
27/03/12

ImmuPharma in talks with a "number of companies" over Lupuzor

Drug discovery specialist ImmuPharma this morning said it is in discussions with a “number of companies” interested in jointly developing its breakthrough drug Lupuzor.
28/02/12

ImmuPharma: A second bite at the cherry, but is the market really plugged into Lupuzor's potential?

Very rarely does a small drug company have the opportunity to do the same transaction twice – with every prospect of getting an even better deal the second time around. But this is exactly what has happened with ImmuPharma.
03/02/12

Something for everyone at next Thursday's Proactive Investors One2One Forum in London: ImmuPharma, O

We have a line-up that offers something for everyone at the Proactive Investors One2One Forum in London next Thursday (February 9). We have ImmuPharma and Oxford Pharmascience presenting alongside Seeing Machines and Probability.
21/11/11

ImmuPharma's Lupuzor offers "blockbuster sales potential", says Merchant Securities

Merchant Securities today initiated coverage of ImmuPharma with a ‘buy’ recommendation and 323 pence share price target. The valuation is based mainly on the potential of the company’s Lupuzor treatment for the auto-immune disease lupus, which has been given the regulatory green light to go into phase III clinical trials.

ImmuPharma PLC market reports

Page 1 of 6

Date	Director	Trans	Amount	Type	Price(p)	Value (£)	Holding	%
24/01/12	A. Agrawal	BUY	62,169	ORD	80.00	49,735	0,000	N/A
23/01/12	F. di Muzio	BUY	60,950	ORD	81.00	49,370	0,000	N/A
23/07/09	D. Dimitriou	SELL	6,250,000	ORD	86.00	5,375,000	3,528,969	4.60
23/07/09	R. Warr	SELL	6,250,000	ORD	86.00	5,375,000	3,528,968	4.60
14/12/07	D. Dimitriou	SELL	900,000	ORD	73.00	657,000	11,878,969	16.32

BASIC RESULTS INFORMATION

Page 1 of 4

Date	Type	Turnover	Profit	EPS (p)	Currency
31/12/11	Full year	0.02	-3.61	-4.12	GBX
30/06/11	Interim	0.01	-2.11	-2.59	GBX
31/12/10	Full year	0.03	-2.47	-2.44	GBX
30/06/10	Interim	0.00	-0.08	-0.10	GBX
31/12/09	Full year	22.06	9.10	10.46	GBX

Additional Information

Share Price

63.13p

Change

0.50

Volume

46,406

Dividend

0

EPS

-2.44

Shares

81.5 m

Offer

63.50

Bid

62.75

Avg. Vol

112,224

Yield

0.00

P/E

10.17

Mkt Cap

51.5 m
Latest Stocktube

13/02/2012
Immupharma CEO says its flagship product, Lupuzor, has great potential
View full size
People interested in this company also viewed
ProactiveInvestors on Facebook

LOGIN

ImmuPharma PLC

Add to watchlist:

ImmuPharma in broker spotlight after bid emerges for rival lupus drug maker

ImmuPharma in talks with a "number of companies" over Lupuzor

ImmuPharma: A second bite at the cherry, but is the market really plugged into Lupuzor's potential?

Something for everyone at next Thursday's Proactive Investors One2One Forum in London: ImmuPharma, O

ImmuPharma's Lupuzor offers "blockbuster sales potential", says Merchant Securities

Sector: Pharmaceuticals & Biotechnology

Immupharma CEO says its flagship product, Lupuzor, has great potential